Elena van Leeuwen @Elena_vLeeuwen

internist-hematoloog. Joined April 2016

Tweets

896
Followers

93
Following

414
Likes

565

Gareth Morgan @DrGarethMorgan1

2 weeks ago

A new contribution from MRC myeloma XI showing that with good diagnostic testing functional high risk is very rare ⁦@MyMKaiser⁩

4 4 14 609 4

Download Image

Blood Academy @blood_academy

2 months ago

2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia nature.com/articles/s4137… What are your thoughts?

1 16 57 5K 42

Download Image

Nitin Jain @NitinJainMD

2 months ago

👉Here is an updated version of the Table which I initially posted post ASH2024. 👉Now Updated with EHA 2025 data including updated FLAIR, CLL13, CAPTIVATE trials. #CLL

5 41 119 11K 58

Download Image

A lot in #mmsm at ASCO. JNJ-5322 is likely the greatest innovation we have seen in a few years. Potential to disrupt our approach to immunotherapy even before we figure out the current players. ⁦@JNJInnovMed⁩ congratulations to the investigators meetings.asco.org/abstracts-pres…

4 18 54 4K 11

Samer Al Hadidi, MD,MS,FACP @HadidiSamer

4 months ago

It will be an interesting discussion but looking at more of those details provided by the briefing , it is becoming clear that there is no clear benefit of early treatment for smoldering myeloma based on what we know #mmsm My recommendedariob will remain to observe all patients…

0 1 6 514 3

Monique Minnema @MinnemaMonique

4 months ago

Answers to a more and more common problem in patients with Waldenstrom's Macroglobulinemia; what to do when progressing on or intolerant of a BTK inhibitor? read our latest publication: doi.org/10.1053/j.semi…

0 3 3 298 0

Andres Gomez @GomezDLeonMD

4 months ago

🚨New milestone for #CARTcell therapy in #GlobalHematology! We report the first successful decentralized, academic-grade CD19 CAR-T manufacturing in healthy donors in Mexico 🇲🇽 and half a dream come true. 📄 JCO Global Oncology: ascopubs.org/doi/10.1200/GO… 1/🧵👇

5 30 88 6K 10

Sanam Loghavi, MD صنم لغوی 🔬🧬 @sanamloghavi

4 months ago

“Bad habits we need to quit” in CML, per @DrHKantarjian @ #ThinkTank25 If you want o hear more, watch the video… it’s gold! @drsangeetmd @CarrawayHetty

2 11 52 4K 16

Download Image

Michael Wang, MD @michaelwangmd

4 months ago

Results from our Phase III ECHO trial of acalabrutinib + BR vs placebo + BR in untreated MCL patients ≥ 65-y.o. showed PFS was substantially improved in the acalabrutinib arm (66.4 vs 49.6 mo., p = 0.016). Toxicity in both arms was manageable. tinyurl.com/ECHO-ABR

3 10 59 4K 10

Download Image

Blood Journals Portfolio @BloodPortfolio

4 months ago

Among patients with negative day 46 MRD, those who also had negative MRD at day 19 have particularly favorable treatment outcomes. ow.ly/z1MK50VHuzH #lymphoidneoplasia #clincialtrialsandobservation #pediatrichematology

0 3 20 2K 1

Download Image

Uriel Suárez @UsuarezMD

4 months ago

Management of MCL. @TheIACH @Mohty_EBMT iach.org/webinars/

0 16 57 5K 26

Download Image

Raul Cordoba, MD, PhD @DrRaulCordoba

4 months ago

#Hematology Early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma: long-term results of a randomised, phase 3 trial - ⁦@TheLancetHaem⁩ #lymsm thelancet.com/journals/lanha…

0 7 21 1K 2

Louise Bringselius @Bringselius

7 months ago

Antalet vårdplatser i svensk sjukvård är betydligt färre än i andra europeiska länder. Vill påminna om det utmärkta förslag som IVO:s tidigare generaldirektör Sofia Wallström lade fram för ett par år sedan, om krav på ett minsta antal. (Statistik nedan ur SvD igår.)

2 11 33 6K 5

Download Image

Saskia Middeldorp @MiddeldorpS

9 months ago

Extended-dose DOAC vs full-dose DOAC #Renove RCT #ASH24 Late breaking abstract. Officially, reduced dose was not non-inferior, but recurrent #VTE rates were low and there is a substantial reduction in major and non-major bleeding. Congrats to @FCouturaud & @INNOVTE1

3 39 110 8K 40

Download Image

Lymphoma Hub @lymphomahub

9 months ago

CONGRESS | #ASH24 | PRESENTATION Marie José Kersten @Kersten_MJ @amsterdamumc highlights results from the ongoing phase I/II ATALANTA-1 trial. GLPG5101 CAR T-cell therapy demonstrated promising efficacy, with CR rates of 100%, 95%, and 54% in patients with R/R MCL, R/R FL/MZL,…

1 9 15 1K 5

Download Image

Ben Derman @bdermanmd

10 months ago

Lots of great #mmsm science to be presented at #ASH24 – here to share some abstracts I’ll be paying special attention to in multiple myeloma with a focus on potential changes to the future care of patients.

1 18 60 12K 24

Rahul Banerjee, MD, FACP @RahulBanerjeeMD

10 months ago

1/ #ASH24 Choosing my top 10 myeloma abstracts this year was harder than ever!! Kudos to all @ASH_hematology authors for GREAT work 👏 For simplicity, I excluded investigational drugs and focused on: 1️⃣ #MMsm response assessments 2️⃣ Optimizing bsAbs 3️⃣ (Soon) practice-changing

3 25 69 13K 51

Download Image

Talha Badar @TalhaBadarMD

10 months ago

Since we are discussing CML for last few weeks and recent asciminib accelerated approval. Sharing this article "food for thought" A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy . therapy failure…

2 12 51 5K 29

Download Image

Ajay Major, MD, MBA @majorajay

11 months ago

Finally! Pembro maint (instead of ASCT) after P-GVD in 2L cHL #ISHL13 (T106): - 40 pts, 25 pembro maint - 2-yr PFS 56% (!!!), worse if Stage IV - 9/10 pts who progressed and went to ASCT are in remission RCT underway, but curve doesn't look great. #lymsm onlinelibrary.wiley.com/doi/full/10.10…

1 11 27 4K 14

Download Image

Ajay Major, MD, MBA @majorajay

11 months ago

UK NLPHL experience #ISHL13: - 203 pts, 64% early-stage - 19% W&W, 41% of those req'd tx median 1.7 yrs later - no survival detriment to initial W&W - no deaths r/t lymphoma NLPHL should be managed as iNHL. #lymsm #nlphlsm